NanoViricides, Inc. is a global leader in the development of nanomedicine drugs against viruses. We have developed two drug candidates that attack SARS-CoV-2 virus that has caused the current global pandemic. Both candidates are broad-spectrum and are expected to continue to work well despite the constant on-going evolution of variants of the virus, unlike vaccines and antibodies.
NV-CoV-2 is the Company’s lead broad-spectrum pan-coronavirus drug candidate. NV-CoV-2 is designed as a nanomachine that attacks the virus particle itself, by binding to the virus particle and engulfing it, thereby rendering it harmless, well beyond what antibodies can do.
NV-CoV-2 has been shown to attack unrelated coronaviruses in cell culture studies effectively. It has also shown very strong effectiveness in animal models of the COVID-19 lung viral disease using a surrogate virus.
We have completed the required non-GLP and GLP safety toxicology studies for NV-CoV-2 candidate to progress into clinical trials.
We have already developed NV-CoV-2 into three different formulations: Injectable, Inhalable, and Oral. We believe that given the strong safety of this drug candidate, it will be possible to develop a highly effective pediatric drug, which is an unmet medical need. We believe NV-CoV-2 will be highly effective as direct inhalation into lungs for severely ill patients, and as injectable therapy for moderately ill patients.
While NV-CoV-2 is designed to attack the virus particle itself and thereby block cellular infection and disease progression, our other drug candidate NV-CoV-2-R additionally blocks the intracellular viral replication as well. We have achieved this by encapsulating remdesivir inside the belly of the NV-CoV-2 nanomachine. With this dual-mode attack, the complete life-cycle of the virus is inhibited, which could potentially result in a cure. There are no other drugs in development against SARS-CoV-2 that block its complete lifecycle to the best of our knowledge.
We are working on putting together human clinical trials for both NV-CoV-2 and NV-CoV-2-R drug candidates at present. We have also developed a novel nanomedicine skin cream, NV-HHV-101 to treat shingles and chickenpox. NV-HHV-101 has completed required GLP safety toxicology studies. We intend to move NV-HHV-101 into clinical trials after the coronavirus drug candidates move further into clinical trials. Additionally, we have several drugs in preclinical development against herpes simplex viruses (HSV-1 that causes cold sores, and HSV-2 that causes genital ulcers), HIV/AIDS, and many other viruses. This broad pipeline is enabled by our unique post-immunotherapeutic “bind-encapsulate-destroy” technology platform. All of our drug candidates are based on broad and exclusive licenses in perpetuity from TheraCour Pharma, Inc.
NanoViricides is unique in the field also in that we have our own multi-kg-scale cGMP-capable clinical drug manufacturing facility. This facility is anticipated to enable rapid translation to the clinic (as opposed to using an external manufacturer) of our drug candidates.
President & Chairman
Dr. Anil R. Diwan is the President and Chairman of NanoViricides, Inc. He has 30+ years of experience in the design, synthesis and characterization of nanomedicines. He invented “TheraCour®” nanomedicines technologies circa 1992 at AllExcel, Inc., a private company he founded. The TheraCour technologies form the basis of the nanoviricides® platform technologies.
Dr. Diwan co-founded NanoViricides, Inc. that was taken public via a reverse shell merger in 2005, and became a reporting company trading on OTC-BB in 2007. He led its up-listing to the NYSE MKT (now American) exchange in September 2013, where the Company trades under the symbol NNVC. Dr. Diwan has also played a lead role in raising over $70M. He developed a cGMP-capable injectables manufacturing suite and a state of the art nanomedicines characterization R&D laboratory by raising private financing on his own, and also played a key role in the design, architecture, and set-up of the facility. This facility was later purchased at cost by NanoViricides, and is now the NanoViricides campus in Shelton, CT. He is intimately involved day-to-day in all of the drug development activities, from design and synthesis to characterization and testing.
Prior to founding AllExcel, Inc., Dr. Diwan performed post-doctoral research in Virology and Biophysics at the University of Connecticut, Storrs, CT. Before that, he did post-doctoral research in Biomedical Engineering at the University of Wisconsin, Madison, WI. He holds a Ph.D. in Biochemical Engineering from Rice University, and a B.Tech. in Chemical Engineering from IIT Bombay.